Clinical trial
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With…
NCT00447226 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00447226 |
|---|---|
| Title | Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists |
| Official title | A Phase II, Placebo Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects With ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Oral lapatinib tablets or placebo tablets |
| Enrollment | 32 |
| Start date | May 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Mar 14, 2007 |
| Last update posted | Jun 12, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: